Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Head & Neck 2CNS 2Other solid neoplasm 1Myeloid 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 62Cyclophosphamide 49fludarabine phosphate 46fludarabine 46Cytarabine 34Decitabine 32venetoclax 27Tacrolimus 21Specimen Handling 21Whole-Body Irradiation 19Mycophenolic Acid 19Melphalan 19Filgrastim 19Busulfan 19Imatinib Mesylate 18ruxolitinib 17Biopsy 15Dasatinib 14Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 13Etoposide 13Clofarabine 13Peripheral Blood Stem Cell Transplantation 12Sirolimus 11Methotrexate 11Ipilimumab 11Injections 11Thiotepa 10Stem Cell Transplantation 10thymoglobulin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × prexasertib × Myeloid × Clear all
NCT03735446 2019-06-12

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Dana-Farber Cancer Institute

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡